<DOC>
	<DOCNO>NCT01337752</DOCNO>
	<brief_summary>The study evaluate effect BHQ880 patient previously untreated multiple myeloma renal insufficiency consider candidate bisphosphonate therapy . The primary objective study evaluate effect BHQ880 combination bortezomib dexamethasone , compare placebo administer combination time first Skeletal Related Event ( SRE ) study .</brief_summary>
	<brief_title>Study Patients With Untreated Multiple Myeloma Renal Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Confirmed diagnosis multiple myeloma 2 . Life expectancy 6 month absence intervention 3 . Must receive previous receive current antimyeloma therapy 4 . Renal insufficiency 5 . Recovered effect prior surgery radiotherapy 1 . Prior IV bisphosphonate therapy time oral bisphosphonate therapy within 4 month study entry 2 . Paget 's disease bone uncorrected hyperparathyroidism 3 . Impaired cardiac function 4 . Known HIV , know active hepatitis B , know suspect hepatitis C infection 5 . Pregnant nursing ( lactate ) woman , 6 . Women childbearing potential , UNLESS agreeable use 2 birth control methods Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>renal insufficiency</keyword>
	<keyword>untreated multiple myeloma</keyword>
</DOC>